A phase 1 trial of human telomerase reverse transcriptase (hTERT) vaccination combined with therapeutic strategies to control immune-suppressor mechanisms
(2024)
Journal Article
Zareian, N., Eremin, O., Pandha, H., Baird, R., Kwatra, V., Funingana, G., Verma, C., Choy, D., Hargreaves, S., Moghimi, P., Shepherd, A., Lobo, D. N., Eremin, J., Farzaneh, F., Kordasti, S., & Spicer, J. (2024). A phase 1 trial of human telomerase reverse transcriptase (hTERT) vaccination combined with therapeutic strategies to control immune-suppressor mechanisms. Experimental Biology and Medicine, 249(1), https://doi.org/10.3389/ebm.2024.10021
The presence of inhibitory immune cells and difficulty in generating activated effector T cells remain obstacles to development of effective cancer vaccines. We designed a vaccine regimen combining human telomerase reverse transcriptase (hTERT) pepti... Read More about A phase 1 trial of human telomerase reverse transcriptase (hTERT) vaccination combined with therapeutic strategies to control immune-suppressor mechanisms.